Yasuhiro Hagiwara

Yasuhiro Hagiwara

Auto-generated profile, based on publicly available information

Yasuhiro Hagiwara

The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
MIMiho Ishimaru
Miho Ishimaru
SOSachiko Ono
Sachiko Ono
KMKojiro Morita
Kojiro Morita
HMHiroki Matsui
Hiroki Matsui
YHYasuhiro Hagiwara
Yasuhiro Hagiwara
HYHideo Yasunaga
Hideo Yasunaga

3 November 2020 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
YHYasuhiro Hagiwara
Yasuhiro Hagiwara
TSTakeru Shiroiwa
Takeru Shiroiwa
NTNaruto Taira
Naruto Taira
TKTakuya Kawahara
Takuya Kawahara
KKKeiko Konomura
Keiko Konomura
KSKojiro Shimozuma
Kojiro Shimozuma
Background: To develop direct and indirect (response) mapping algorithms from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy General (FACT-G) onto the EQ-5D-5L index. Methods: We conducted the QOL-MAC study where EQ-5D-5L, EORTC QLQ-C30, and FACT-G were cross-sectionally evaluated in patients receiving drug treatment for solid tumors in Japan. We developed direct and indirect mapping algorithms using 7 regression methods. Direct mapping was based on the Japanese value set. We evaluated the predictive performances based on root mean squared error (RMSE), mean absolute error, and correlation between the observed and predicted EQ-5D-5L indexes. Results: Based on data from 903 and 908 patients for EORTC QLQ-C30 and FACT-G, respectively, we recommend two-part beta regression for direct mapping and ordinal logistic regression for indirect mapping for both EORTC QLQ-C30 and FACT-G. Cross-validated RMSE were 0.101 in the two methods for EORTC QLQ-C30, whereas they were 0.121 in two-part beta regression and 0.120 in ordinal logistic regression for FACT-G. The mean EQ-5D-5L index and cumulative distribution function simulated from the recommended mapping algorithms generally matched with the observed ones except for very good health (both source measures) and poor health (only FACT-G). Conclusions: The developed mapping algorithms can be used to generate the EQ-5D-5L index from EORTC QLQ-C30 or FACT-G in cost-effectiveness analyses, whose predictive performance would be similar to or better than those of previous algorithms.

17 October 2017 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
YHYasuhiro Hagiwara
Yasuhiro Hagiwara
TSTakeru Shiroiwa
Takeru Shiroiwa
KSKojiro Shimozuma
Kojiro Shimozuma
TKTakuya Kawahara
Takuya Kawahara
YUYukari Uemura
Yukari Uemura
HMHirofumi Mukai
Hirofumi Mukai
Objective The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. Methods We analyzed the data from the SELECT BC study, a multicenter, open-label, randomized, phase III study conducted in Japan, which compared first-line S-1 with taxane therapies. Heath utility and HRQOL were assessed using the EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 3, 6, and 12 months after treatment initiation. Health utility was calculated based on societal preferences, and AEs were reported at each cycle of the study treatment. Linear marginal mean models were used to quantify the impact of the last AEs (with 10 or more incidences) observed before HRQOL assessment on health utility and HRQOL. Results Analysis included 380 patients and 12 (of 15) AEs. Grade 1 nausea and oral mucositis, grade 1 and 2 edema, and grade 2 fatigue, motor and sensory neuropathy, and myalgia were significantly associated with disutility, measured using the EQ-5D-3L. Grade 1 oral mucositis, grade 1 and 2 fatigue, and grade 2 sensory neuropathy were significantly associated with impaired global health status in the EORTC QLQ-C30. AEs associated with decrements in the five functioning scales included fatigue, oral mucositis, nausea, edema, motor and sensory neuropathy, and myalgia. Conclusions We reported disutilities caused by AEs in patients with metastatic breast cancer under chemotherapy. These findings can be applied to future model-based cost-effectiveness analyses. Trial Registration Number C000000416.

4 November 2019 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
TYTakuo Yoshida
Takuo Yoshida
SUShigehiko Uchino
Shigehiko Uchino
YSYusuke Sasabuchi
Yusuke Sasabuchi
YHYasuhiro Hagiwara
Yasuhiro Hagiwara

1 April 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
YHYasuhiro Hagiwara
Yasuhiro Hagiwara
YOYasuo Ohashi
Yasuo Ohashi
KUKatsuhiko Uesaka
Katsuhiko Uesaka
NBNarikazu Boku
Narikazu Boku
AFAkira Fukutomi
Akira Fukutomi
TSTakeshi Sudo
Takeshi Sudo

23 May 2024 in Statistical Methods in Medical Research
Verified
Journal Article
Closed access
YHYasuhiro Hagiwara
Yasuhiro Hagiwara
YMYutaka Matsuyama
Yutaka Matsuyama
Modified Poisson regression, which estimates the regression parameters in the log-binomial regression model using the Poisson quasi-likelihood estimating equation and robust variance, is a useful tool for estimating the adjusted risk and prevalence ratio in binary outcome analysis. Although several goodness-of-fit tests have been developed for other binary regressions, few goodness-of-fit tests are available for modified Poisson regression. In this study, we proposed several goodness-of-fit tests for modified Poisson regression, including the modified Hosmer-Lemeshow test with empirical variance, Tsiatis test, normalized Pearson chi-square tests with binomial variance and Poisson variance, and normalized residual sum of squares test. The original Hosmer-Lemeshow test and normalized Pearson chi-square test with binomial variance are inappropriate for the modified Poisson regression, which can produce a fitted value exceeding 1 owing to the unconstrained parameter space. A simulation study revealed that the normalized residual sum of squares test performed well regarding the type I error probability and the power for a wrong link function. We applied the proposed goodness-of-fit tests to the analysis of cross-sectional data of patients with cancer. We recommend the normalized residual sum of squares test as a goodness-of-fit test in the modified Poisson regression.